Halozyme to Report Third Quarter 2026 Financial and Operating Results
PR Newswire•22/10/2026•08:30 ET
0
Key Highlights
- ➤Halozyme will release Q3 2026 results November 5 after market close
- ➤Conference call scheduled November 5 at 1:30pm PT/4:30pm ET
- ➤ENHANZE has reached more than one million patient lives globally
- ➤Ten ENHANZE products are commercialized across over 100 global markets
- ➤Hypercon technology licensed to Janssen, Eli Lilly, argenx, Vertex and Oruka
Halozyme to Report Third Quarter 2026 Financial and Operating Results PR Newswire
SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, following the close of trading.
Get started
Create a free account to read the full story.